Thyroid Dysfunction in Heart Failure and Cardiovascular Outcomes

Lakshmi Kannan, Pamela A. Shaw, Michael P. Morley, Jeffrey Brandimarto, James C. Fang, Nancy K Sweitzer, Thomas P. Cappola, Anne R. Cappola

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

BACKGROUND: The effects of thyroid dysfunction in patients with preexisting heart failure have not been adequately studied. We examined the prevalence of thyroid dysfunction and associations with cardiovascular outcomes in a large, prospective cohort of outpatients with preexisting heart failure. METHODS AND RESULTS: We examined associations between thyroid dysfunction and New York Heart Association class, atrial fibrillation, and a composite end point of ventricular assist device placement, heart transplantation, or death in 1365 participants with heart failure enrolled in the Penn Heart Failure Study. Mean age was 57 years, 35% were women, and the majority had New York Heart Association class II (45%) or III (32%) symptoms. More severe heart failure was associated with higher thyroid-stimulating hormone (TSH), higher free thyroxine (FT4), and lower total triiodothyronine (TT3) concentrations ( P<0.001 all models). Atrial fibrillation was positively associated with higher levels of FT4 alone ( P≤0.01 all models). There were 462 composite end points over a median 4.2 years of follow-up. In adjusted models, compared with euthyroidism, subclinical hypothyroidism (TSH 4.51-19.99 mIU/L with normal FT4) was associated with an increased risk of the composite end point overall (hazard ratio, 1.82; 95% CI, 1.27-2.61; P=0.001) and in the subgroup with TSH ≥7.00 mIU/L (hazard ratio, 3.25; 95% CI, 1.96-5.39; P<0.001), but not in the subgroup with TSH 4.51-6.99 mIU/L (hazard ratio, 1.26; 95% CI, 0.78-2.06; P=0.34). Isolated low T3 was also associated with the composite end point (hazard ratio, 2.12; 95% CI, 1.65-2.72; P<0.001). CONCLUSIONS: In patients with preexisting heart failure, subclinical hypothyroidism with TSH ≥7 mIU/L and isolated low T3 levels are associated with poor prognosis. Clinical trials are needed to explore therapeutic effects of T4 and T3 administration in heart failure.

Original languageEnglish (US)
Pages (from-to)e005266
JournalCirculation. Heart failure
Volume11
Issue number12
DOIs
StatePublished - Dec 1 2018

Fingerprint

Thyroid Gland
Heart Failure
Thyrotropin
Hypothyroidism
Atrial Fibrillation
Heart-Assist Devices
Triiodothyronine
Therapeutic Uses
Heart Transplantation
Thyroxine
Outpatients
Clinical Trials

Keywords

  • atrial fibrillation
  • euthyroid sick syndromes
  • heart failure
  • heart transplantation
  • hypothyroidism
  • thyroid diseases

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Kannan, L., Shaw, P. A., Morley, M. P., Brandimarto, J., Fang, J. C., Sweitzer, N. K., ... Cappola, A. R. (2018). Thyroid Dysfunction in Heart Failure and Cardiovascular Outcomes. Circulation. Heart failure, 11(12), e005266. https://doi.org/10.1161/CIRCHEARTFAILURE.118.005266

Thyroid Dysfunction in Heart Failure and Cardiovascular Outcomes. / Kannan, Lakshmi; Shaw, Pamela A.; Morley, Michael P.; Brandimarto, Jeffrey; Fang, James C.; Sweitzer, Nancy K; Cappola, Thomas P.; Cappola, Anne R.

In: Circulation. Heart failure, Vol. 11, No. 12, 01.12.2018, p. e005266.

Research output: Contribution to journalArticle

Kannan, L, Shaw, PA, Morley, MP, Brandimarto, J, Fang, JC, Sweitzer, NK, Cappola, TP & Cappola, AR 2018, 'Thyroid Dysfunction in Heart Failure and Cardiovascular Outcomes', Circulation. Heart failure, vol. 11, no. 12, pp. e005266. https://doi.org/10.1161/CIRCHEARTFAILURE.118.005266
Kannan, Lakshmi ; Shaw, Pamela A. ; Morley, Michael P. ; Brandimarto, Jeffrey ; Fang, James C. ; Sweitzer, Nancy K ; Cappola, Thomas P. ; Cappola, Anne R. / Thyroid Dysfunction in Heart Failure and Cardiovascular Outcomes. In: Circulation. Heart failure. 2018 ; Vol. 11, No. 12. pp. e005266.
@article{bd07488b836e4defa48d290ba48a4808,
title = "Thyroid Dysfunction in Heart Failure and Cardiovascular Outcomes",
abstract = "BACKGROUND: The effects of thyroid dysfunction in patients with preexisting heart failure have not been adequately studied. We examined the prevalence of thyroid dysfunction and associations with cardiovascular outcomes in a large, prospective cohort of outpatients with preexisting heart failure. METHODS AND RESULTS: We examined associations between thyroid dysfunction and New York Heart Association class, atrial fibrillation, and a composite end point of ventricular assist device placement, heart transplantation, or death in 1365 participants with heart failure enrolled in the Penn Heart Failure Study. Mean age was 57 years, 35{\%} were women, and the majority had New York Heart Association class II (45{\%}) or III (32{\%}) symptoms. More severe heart failure was associated with higher thyroid-stimulating hormone (TSH), higher free thyroxine (FT4), and lower total triiodothyronine (TT3) concentrations ( P<0.001 all models). Atrial fibrillation was positively associated with higher levels of FT4 alone ( P≤0.01 all models). There were 462 composite end points over a median 4.2 years of follow-up. In adjusted models, compared with euthyroidism, subclinical hypothyroidism (TSH 4.51-19.99 mIU/L with normal FT4) was associated with an increased risk of the composite end point overall (hazard ratio, 1.82; 95{\%} CI, 1.27-2.61; P=0.001) and in the subgroup with TSH ≥7.00 mIU/L (hazard ratio, 3.25; 95{\%} CI, 1.96-5.39; P<0.001), but not in the subgroup with TSH 4.51-6.99 mIU/L (hazard ratio, 1.26; 95{\%} CI, 0.78-2.06; P=0.34). Isolated low T3 was also associated with the composite end point (hazard ratio, 2.12; 95{\%} CI, 1.65-2.72; P<0.001). CONCLUSIONS: In patients with preexisting heart failure, subclinical hypothyroidism with TSH ≥7 mIU/L and isolated low T3 levels are associated with poor prognosis. Clinical trials are needed to explore therapeutic effects of T4 and T3 administration in heart failure.",
keywords = "atrial fibrillation, euthyroid sick syndromes, heart failure, heart transplantation, hypothyroidism, thyroid diseases",
author = "Lakshmi Kannan and Shaw, {Pamela A.} and Morley, {Michael P.} and Jeffrey Brandimarto and Fang, {James C.} and Sweitzer, {Nancy K} and Cappola, {Thomas P.} and Cappola, {Anne R.}",
year = "2018",
month = "12",
day = "1",
doi = "10.1161/CIRCHEARTFAILURE.118.005266",
language = "English (US)",
volume = "11",
pages = "e005266",
journal = "Circulation: Heart Failure",
issn = "1941-3297",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - Thyroid Dysfunction in Heart Failure and Cardiovascular Outcomes

AU - Kannan, Lakshmi

AU - Shaw, Pamela A.

AU - Morley, Michael P.

AU - Brandimarto, Jeffrey

AU - Fang, James C.

AU - Sweitzer, Nancy K

AU - Cappola, Thomas P.

AU - Cappola, Anne R.

PY - 2018/12/1

Y1 - 2018/12/1

N2 - BACKGROUND: The effects of thyroid dysfunction in patients with preexisting heart failure have not been adequately studied. We examined the prevalence of thyroid dysfunction and associations with cardiovascular outcomes in a large, prospective cohort of outpatients with preexisting heart failure. METHODS AND RESULTS: We examined associations between thyroid dysfunction and New York Heart Association class, atrial fibrillation, and a composite end point of ventricular assist device placement, heart transplantation, or death in 1365 participants with heart failure enrolled in the Penn Heart Failure Study. Mean age was 57 years, 35% were women, and the majority had New York Heart Association class II (45%) or III (32%) symptoms. More severe heart failure was associated with higher thyroid-stimulating hormone (TSH), higher free thyroxine (FT4), and lower total triiodothyronine (TT3) concentrations ( P<0.001 all models). Atrial fibrillation was positively associated with higher levels of FT4 alone ( P≤0.01 all models). There were 462 composite end points over a median 4.2 years of follow-up. In adjusted models, compared with euthyroidism, subclinical hypothyroidism (TSH 4.51-19.99 mIU/L with normal FT4) was associated with an increased risk of the composite end point overall (hazard ratio, 1.82; 95% CI, 1.27-2.61; P=0.001) and in the subgroup with TSH ≥7.00 mIU/L (hazard ratio, 3.25; 95% CI, 1.96-5.39; P<0.001), but not in the subgroup with TSH 4.51-6.99 mIU/L (hazard ratio, 1.26; 95% CI, 0.78-2.06; P=0.34). Isolated low T3 was also associated with the composite end point (hazard ratio, 2.12; 95% CI, 1.65-2.72; P<0.001). CONCLUSIONS: In patients with preexisting heart failure, subclinical hypothyroidism with TSH ≥7 mIU/L and isolated low T3 levels are associated with poor prognosis. Clinical trials are needed to explore therapeutic effects of T4 and T3 administration in heart failure.

AB - BACKGROUND: The effects of thyroid dysfunction in patients with preexisting heart failure have not been adequately studied. We examined the prevalence of thyroid dysfunction and associations with cardiovascular outcomes in a large, prospective cohort of outpatients with preexisting heart failure. METHODS AND RESULTS: We examined associations between thyroid dysfunction and New York Heart Association class, atrial fibrillation, and a composite end point of ventricular assist device placement, heart transplantation, or death in 1365 participants with heart failure enrolled in the Penn Heart Failure Study. Mean age was 57 years, 35% were women, and the majority had New York Heart Association class II (45%) or III (32%) symptoms. More severe heart failure was associated with higher thyroid-stimulating hormone (TSH), higher free thyroxine (FT4), and lower total triiodothyronine (TT3) concentrations ( P<0.001 all models). Atrial fibrillation was positively associated with higher levels of FT4 alone ( P≤0.01 all models). There were 462 composite end points over a median 4.2 years of follow-up. In adjusted models, compared with euthyroidism, subclinical hypothyroidism (TSH 4.51-19.99 mIU/L with normal FT4) was associated with an increased risk of the composite end point overall (hazard ratio, 1.82; 95% CI, 1.27-2.61; P=0.001) and in the subgroup with TSH ≥7.00 mIU/L (hazard ratio, 3.25; 95% CI, 1.96-5.39; P<0.001), but not in the subgroup with TSH 4.51-6.99 mIU/L (hazard ratio, 1.26; 95% CI, 0.78-2.06; P=0.34). Isolated low T3 was also associated with the composite end point (hazard ratio, 2.12; 95% CI, 1.65-2.72; P<0.001). CONCLUSIONS: In patients with preexisting heart failure, subclinical hypothyroidism with TSH ≥7 mIU/L and isolated low T3 levels are associated with poor prognosis. Clinical trials are needed to explore therapeutic effects of T4 and T3 administration in heart failure.

KW - atrial fibrillation

KW - euthyroid sick syndromes

KW - heart failure

KW - heart transplantation

KW - hypothyroidism

KW - thyroid diseases

UR - http://www.scopus.com/inward/record.url?scp=85058876896&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058876896&partnerID=8YFLogxK

U2 - 10.1161/CIRCHEARTFAILURE.118.005266

DO - 10.1161/CIRCHEARTFAILURE.118.005266

M3 - Article

C2 - 30562095

AN - SCOPUS:85058876896

VL - 11

SP - e005266

JO - Circulation: Heart Failure

JF - Circulation: Heart Failure

SN - 1941-3297

IS - 12

ER -